CBD shows multiple anti-tumor mechanisms against pancreatic cancer in lab studies
A systematic review of 15 studies found CBD attacked pancreatic cancer cells through multiple pathways and enhanced chemotherapy effectiveness, but clinical evidence remains absent.
Quick Facts
What This Study Found
CBD exhibited antitumor properties through ER stress and apoptosis (via CerS1), GPR55/MAPK inhibition, immune modulation, and chemosensitization to gemcitabine. Combination therapies with other cannabinoids or chemotherapeutics enhanced outcomes in preclinical models.
Key Numbers
15 studies met inclusion criteria. CBD pathways identified: CerS1-mediated ER stress, GPR55/MAPK inhibition, immune modulation, gemcitabine chemosensitization. Combination therapies outperformed CBD alone in preclinical models.
How They Did This
Systematic review of PubMed, Scopus, Web of Science, EMBASE, and Google Scholar (2006-2025), including 15 studies examining CBD's effects on pancreatic ductal adenocarcinoma in vitro, in vivo, and clinical contexts.
Why This Research Matters
Pancreatic cancer has the worst survival rate of any common cancer and desperately needs new treatment approaches. CBD's ability to attack tumor cells through multiple pathways and sensitize them to chemotherapy warrants further investigation.
The Bigger Picture
Pancreatic cancer's treatment resistance stems partly from its ability to evade single-pathway therapies. CBD's multi-target approach, particularly its chemosensitization effects, could potentially complement existing treatments if validated clinically.
What This Study Doesn't Tell Us
Almost entirely preclinical evidence. No controlled clinical trials exist. CBD doses used in lab studies may not be achievable in patients. Publication bias may favor positive preclinical results.
Questions This Raises
- ?Can therapeutic CBD concentrations be achieved at the tumor site?
- ?Would CBD improve gemcitabine outcomes in a clinical trial?
Trust & Context
- Key Stat:
- CBD enhanced gemcitabine chemotherapy effectiveness in preclinical models
- Evidence Grade:
- Systematic review is thorough but the underlying evidence is almost entirely preclinical. No clinical efficacy data exists for this indication.
- Study Age:
- Published in 2025, literature 2006-2025.
- Original Title:
- Cannabidiol in pancreatic ductal adenocarcinoma: preclinical evidence, molecular mechanisms, and translational challenges.
- Published In:
- Cancer cell international, 25(1), 415 (2025)
- Authors:
- Esmaeli, Mojtaba(4), Dehghanpour Dehabadi, Maryam(4), Khaleghi, Ali Asghar
- Database ID:
- RTHC-06413
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Could CBD help treat pancreatic cancer?
Lab studies show CBD attacks pancreatic cancer cells through multiple pathways and may enhance chemotherapy. However, no clinical trials have tested this in patients, so it remains a preclinical possibility.
How does CBD fight cancer cells in the lab?
CBD was found to trigger cancer cell death through ER stress and apoptosis, inhibit growth signals (GPR55/MAPK), modulate the immune response, and make cancer cells more sensitive to the chemotherapy drug gemcitabine.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-06413APA
Esmaeli, Mojtaba; Dehghanpour Dehabadi, Maryam; Khaleghi, Ali Asghar. (2025). Cannabidiol in pancreatic ductal adenocarcinoma: preclinical evidence, molecular mechanisms, and translational challenges.. Cancer cell international, 25(1), 415. https://doi.org/10.1186/s12935-025-04062-9
MLA
Esmaeli, Mojtaba, et al. "Cannabidiol in pancreatic ductal adenocarcinoma: preclinical evidence, molecular mechanisms, and translational challenges.." Cancer cell international, 2025. https://doi.org/10.1186/s12935-025-04062-9
RethinkTHC
RethinkTHC Research Database. "Cannabidiol in pancreatic ductal adenocarcinoma: preclinical..." RTHC-06413. Retrieved from https://rethinkthc.com/research/esmaeli-2025-cannabidiol-in-pancreatic-ductal
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.